

Ardea Biosciences, Inc./DE  
Form POS AM  
June 20, 2012  
**Table of Contents**

**AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 19, 2012**

**Registration Statement File No. 333-82934**

**Registration Statement File No. 333-89840**

**Registration Statement File No. 333-101633**

**Registration Statement File No. 333-105288**

**Registration Statement File No. 333-110197**

**Registration Statement File No. 333-148765**

**Registration Statement File No. 333-153215**

**Registration Statement File No. 333-156708**

**Registration Statement File No. 333-159279**

**Registration Statement File No. 333-165909**

**Registration Statement File No. 333-170105**

**Registration Statement File No. 333-178746**

**Registration Statement File No. 333-179296**

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-82934**

**Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-89840**

**Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-101633**

**Post-Effective Amendment No. 3 to Form S-3 Registration Statement No. 333-105288**

**Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-110197**

**Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-148765**

**Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-153215**

**Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-156708**

**Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-159279**

**Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-165909**

**Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-170105**

**Post-Effective Amendment No. 2 to Form S-3 Registration Statement No. 333-178746**

**Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-179296**

*UNDER*

*THE SECURITIES ACT OF 1933*

## **ARDEA BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**94-3200380**  
(I.R.S. Employer  
Identification Number)

**4939 Directors Place**

**San Diego, CA 92121**

**(858) 652-6500**

(Address, including zip code, and telephone number, including area code,

of registrant's principal executive offices)



**Table of Contents**

**Barry D. Quart, Pharm.D.**

**Chief Executive Officer**

**Ardea Biosciences, Inc.**

**4939 Directors Place**

**San Diego, CA 92121**

**(858) 652-6500**

**(Name, address, including zip code, and telephone number,  
including area code, of agent for service)**

*Copies to:*

**Catherine J. Dargan**

**Covington & Burling LLP**

**1201 Pennsylvania Avenue, NW**

**Washington, DC 20004**

**Not applicable.**

**(Approximate date of commencement of proposed sale to the public)**

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. "

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. "

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. "

## Edgar Filing: Ardea Biosciences, Inc./DE - Form POS AM

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

|                         |                                                                        |                           |                                     |
|-------------------------|------------------------------------------------------------------------|---------------------------|-------------------------------------|
| Large accelerated filer | <input type="checkbox"/>                                               | Accelerated filer         | <input checked="" type="checkbox"/> |
| Non-accelerated filer   | <input type="checkbox"/> (Do not check if a smaller reporting company) | Smaller reporting company | <input type="checkbox"/>            |

**Table of Contents**

**This Post-Effective Amendment to the Registration Statements on Form S-3 listed above shall become effective on such date as the Securities and Exchange Commission, acting pursuant to Section 8(c) of the Securities Act of 1933, as amended, may determine.**

**Table of Contents**

**TABLE OF CONTENTS**

EXPLANATORY NOTE

SIGNATURES

**Table of Contents**

**EXPLANATORY NOTE**

On June 19, 2012, pursuant to an Agreement and Plan of Merger, dated as of April 21, 2012 (the Merger Agreement ), by and among Ardea Biosciences, Inc., a Delaware corporation (the Company ), Zeneca Inc., a Delaware corporation ( Zeneca ), and QAM Corp., a Delaware corporation and wholly owned subsidiary of Zeneca ( Merger Sub ), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Zeneca (the Merger ). In connection with the Merger, the Company has terminated all offerings of the Company s securities pursuant to the Registration Statements on Form S-3 (File Nos. 333-82934, 333-89840, 333-101633, 333-105288, 333-110197, 333-148765, 333-153215, 333-156708, 333-159279, 333-165909, 333-170105, 333-178746 and 333-179296), each as amended (as applicable) (the Registration Statements ).

This Post-Effective Amendment to the Registration Statements is being filed solely for the purpose of deregistering any and all securities previously registered under the Registration Statements that remain unsold.



**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of San Diego, State of California, on June 19, 2012.

**ARDEA BIOSCIENCES, INC.**

By: /s/ Barry Quart  
 Barry Quart  
 President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment to the Registration Statements has been signed below by the following persons in the capacities and on the dates indicated.

| Signatures                                                         | Title                                                                                                                              | Date                 |
|--------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| <p><b>/s/ Barry Quart</b><br/>                     Barry Quart</p> | <p>President and Chief Executive<br/>                     Officer<br/><br/> <i>(Principal Executive Officer)</i></p>               | <p>June 19, 2012</p> |
| <p><b>/s/ John Beck</b><br/>                     John Beck</p>     | <p>Chief Financial Officer<br/> <i>(Principal Financial Officer and<br/>                     Principal Accounting Officer)</i></p> | <p>June 19, 2012</p> |